Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline
December 12, 2017 – AJMC Staff
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 11, 2017 – Jaime Rosenberg
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg
What We're Reading: Harsh Flu Season; Potential Hospital Giants Merger; ACA Sign-Up Deadline
December 11, 2017 – AJMC Staff
ICER Seeking Public Comment About Migraine, Plaque Psoriasis Treatments
December 11, 2017 – Allison Inserro
ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure
December 10, 2017 – Mary Caffrey
Heavy Healthcare Use Precedes Start of Acthar Injection for Patients With Rare Infantile Spasms
December 09, 2017 – Mary Caffrey
UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor
December 08, 2017 – Kelly Davio

CYRAMZA Meets Secondary Endpoints in Phase 3 REACH Trial for HCC

CYRAMZA™ (ramucirumab)did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant, in patients with hepatocellular carcinoma, but meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression were observed.

Eli Lilly and Company (NYSE: LLY) today announced that the Phase 3 REACH trial of CYRAMZA™ (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant.  Encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression.

The global, randomized, double-blind REACH trial compared CYRAMZA plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma (HCC) after being treated with sorafenib in the first-line setting.  The top-line safety data were consistent with what was seen in previous single-agent CYRAMZA studies. The most common ( > 5% incidence) grade > /=3 adverse events occurring at a higher rate on the CYRAMZA arm compared to the control arm were hypertension and asthenia (fatigue).

"Although the REACH study did not achieve statistical significance for survival, we are encouraged by the efficacy seen overall, especially in specific subpopulations. We plan to discuss these results with regulatory authorities," said Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly Oncology.

Source: Eli Lilly


 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!